Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) Bermuda 98-1327726 (I.R ...

F EB RUARY 28, 2023 | --- | |-----------------------------------------------------------------------------------------------| | | | Introduction \| Sanj K. Patel, Chief Executive Officer | | ARCALYST ® Commercial Execution \| Ross Moat, Chief Commercial Officer | | Fourth Quarter and Full-Year 2022 Financial Results \| Mark Ragosa, Chief Financial Officer | | Closing Remarks \| Sanj K. Patel, Chief Executive Officer | | Q&A Session | Forward Looking Statements This presentation (together with any other stat ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer Eben Tessari - Chief Operating Officer John Paolini - Chief Medical Officer Conference Call Participants Anupam Rama - JP Morgan Paul Choi - Goldman Sachs David Nierengarten - Wedbush Geoff Meacham - Bank of America Liisa Bayko - Ev ...

Pharmacokinetic Simulations PHARMACOKINETICS (PK) LEAD-IN PROOF-OF-CONCEPT AMENDED COHORT 3 (Proof of Concept) 0 200 400 600 800 Addressable US Prevalence (in thousands) 14 KPL-404: Potentially Best-in-Class, Subcutaneously Delivered Monoclonal Antibody Inhibitor 10 11 COHORTS 1-2 (PK Lead-In) Pacific Region (Excluding Japan) Kiniksa is also eligible to receive royalties on annual net sales ranging from low-double digits to mid-teens, before fulfilling upstream financial obligations 16 • Quickly took asset ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K. Patel – Chief Executive Officer John Paolini – Chief Medical Officer Ross Moat – Chief Commercial Officer Mark Ragosa – Chief Financial Officer Eben Tessari – Chief Operating Officer Conference Call Participants Anupam Rama – JPMorgan Paul Choi – Goldman Sachs Alex Hammond – Bank of America Operator Good day and thank you for standing ...

| --- | --- | --- | --- | --- | |-----------------------|-------|-------|-------|-------| | | | | | | | Third Quarter 2022 | | | | | | | | | | | | Financial Results and | | | | | NOVEMB ER 1, 2022 Agenda | --- | |--------------------------------------------------------------------------------| | Introduction \| Sanj K. Patel, Chief Executive Officer | | Clinical Update \| John F. Paolini, Chief Medical Officer | | ARCALYST ® Commercial Execution \| Ross Moat, Chief Commercial Officer | | Third Quarter 2022 ...

Corporate Presentation AUGUST 2022 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, "Kiniksa," "we," "us" or "our"). In some cases, you can identify forward looking statements by t ...

Financial Data and Key Metrics Changes - Kiniksa Pharmaceuticals reported net revenue for ARCALYST of $27 million in Q2 2022, representing approximately 22% growth over Q1 2022 [9][35] - Total operating expenses decreased year-over-year to approximately $46.3 million, and net loss was approximately $20 million [36] - The company ended Q2 2022 with a cash balance of approximately $138 million, which is expected to fund operations into at least 2025 [37][40] Business Line Data and Key Metrics Changes - The ARCALYST franchise showed strong performance with a quarterly growth of 22%, driven by increased patient identification and demand in recurrent pericarditis [18][32] - The number of prescribers for ARCALYST grew to over 550 since launch, with a significant increase in repeat prescribers [19][20] - Patient satisfaction ratings for ARCALYST exceeded 90%, indicating positive reception among patients [23] Market Data and Key Metrics Changes - The total addressable market for recurrent pericarditis is estimated at 14,000 patients with two or more recurrences annually, presenting a significant growth opportunity for ARCALYST [24] - The company plans to expand its field team from approximately 30 to 50 representatives to cover a larger portion of the recurrent pericarditis patient population [30] Company Strategy and Development Direction - Kiniksa aims to leverage the $100 million received from the licensing agreement with Roche and Genentech to invest in synergistic opportunities across its portfolio, particularly in the cardiovascular space [7][52] - The company is focused on building a foundation as an emerging leader in immune-modulating therapies while continuing to execute on its current portfolio [39][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth trajectory of ARCALYST, guiding for total net revenue of $115 million to $130 million for 2022 [33][40] - The company remains well-capitalized and expects to fund its operations through at least 2025, allowing for strategic investments in its pipeline and commercial efforts [37][40] Other Important Information - Kiniksa has completed patient screening for the Phase 2 clinical trial of Vixarelimab and plans to complete this trial without disclosing data in the second half of 2022 [14][15] - The company is also conducting a Phase 2 clinical trial of KPL-404 in rheumatoid arthritis, focusing on efficacy and safety [11] Q&A Session Summary Question: Near-term ARCALYST dynamics and sales force expansion opportunities - Management highlighted the focus on increasing the number of prescribers and driving repeat prescriptions while maintaining high compliance and patient education [45][46] Question: Experience of prescribers and peer-to-peer education - Management noted that as prescribers gain experience with ARCALYST, they are likely to share their positive experiences with colleagues, enhancing the prescribing base [47][48] Question: Synergistic opportunities from the Vixa transaction - Management confirmed that the proceeds will be used for business development and to augment the portfolio with immune-modulating therapies, while also progressing existing assets like KPL-404 and Mavri [51][53] Question: Upfront payment from Genentech and revenue recognition - The upfront payment consists of $80 million immediately and $20 million in supply obligations, with details on revenue recognition still being finalized [57][58] Question: Royalty rates from the Genentech agreement - The royalty rates on annual net sales are expected to range from low double digits to mid-teens [59] Question: Current pipeline priorities and business development focus - Management emphasized a high bar for bringing new programs into the pipeline while remaining active in exploring external opportunities [60][61]

| --- | --- | --- | --- | |-----------------------|-------|-------|-------| | | | | | | Second Quarter 2022 | | | | | | | | | | Financial Results and | | | | AUG UST 3, 2022 Agenda | --- | --- | |---------------------------------------------------------------------------------------|-------| | Introduction \| Sanj K. Patel, Chief Executive Officer | | | Review of License Agreement for Vixarelimab \| Eben Tessari, Chief Operating Officer | | | ARCALYST ® Commercial Execution \| Ross Moat, Chief Commercial Of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Incorporation or Organization) Identification No.) Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton HM11, Bermuda FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co ...